Literature DB >> 12208944

Susceptibility to polyomavirus-induced tumors in inbred mice: role of innate immune responses.

Palanivel Velupillai1, John P Carroll, Thomas L Benjamin.   

Abstract

Mice of the PERA/Ei strain (PE mice) are highly susceptible to tumor induction by polyomavirus and transmit their susceptibility in a dominant manner in crosses with resistant C57BR/cdJ mice (BR mice). BR mice respond to polyomavirus infection with a type 1 cytokine response and develop effective cell-mediated immunity to the virus-induced tumors. By enumerating virus-specific CD8(+) T cells and measuring cytokine responses, we show that the susceptibility of PE mice is due to the absence of a type 1 cytokine response and a concomitant failure to sustain virus-specific cytotoxic T lymphocytes. (PE x BR)F(1) mice showed an initial type 1 response that became skewed toward type 2. Culture supernatants of splenocytes from infected PE mice stimulated in vitro contained high levels of interleukin-10 and no detectable gamma interferon, while those from BR mice showed the opposite pattern. Differences in the innate immune response to polyomavirus by antigen-presenting cells in PE mice and BR mice led to polarization of T-cell cytokine responses. Adherent cells from spleens of infected BR mice produced high levels of interleukin-12, while those from infected PE and F(1) mice produced predominantly interleukin-10. PE and F(1) mice infected by polyomavirus responded with increases in antigen-presenting cells expressing B7.2 costimulatory molecules, whereas BR mice responded with increased expression of B7.1. Administration of recombinant interleukin-12 along with virus resulted in partial protection of PE mice and provided complete protection against tumor development in F(1) animals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208944      PMCID: PMC136524          DOI: 10.1128/jvi.76.19.9657-9663.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

Review 1.  Polyoma virus: old findings and new challenges.

Authors:  T L Benjamin
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

2.  Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.

Authors:  P Lee; F Wang; J Kuniyoshi; V Rubio; T Stuges; S Groshen; C Gee; R Lau; G Jeffery; K Margolin; V Marty; J Weber
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

3.  The role for interleukin-12 therapy of cutaneous T cell lymphoma.

Authors:  A H Rook; M H Zaki; M Wysocka; G S Wood; M Duvic; L C Showe; F Foss; M Shapiro; T M Kuzel; E A Olsen; E C Vonderheid; R Laliberte; M L Sherman
Journal:  Ann N Y Acad Sci       Date:  2001-09       Impact factor: 5.691

4.  Wild-derived inbred mice have a novel basis of susceptibility to polyomavirus-induced tumors.

Authors:  P Velupillai; I Yoshizawa; D C Dey; S R Nahill; J P Carroll; R T Bronson; T L Benjamin
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 5.  Immunity to polyoma virus infection and tumorigenesis.

Authors:  J M Moser; A E Lukacher
Journal:  Viral Immunol       Date:  2001       Impact factor: 2.257

6.  Accelerated development of polyoma tumors and embryonic lethality: different effects of p53 loss on related mouse backgrounds.

Authors:  D C Dey; R P Bronson; J Dahl; J P Carroll; T L Benjamin
Journal:  Cell Growth Differ       Date:  2000-05

7.  Visualization of polyoma virus-specific CD8+ T cells in vivo during infection and tumor rejection.

Authors:  A E Lukacher; J M Moser; A Hadley; J D Altman
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

8.  Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.

Authors:  T Tatsumi; T Takehara; T Kanto; T Miyagi; N Kuzushita; Y Sugimoto; M Jinushi; A Kasahara; Y Sasaki; M Hori; N Hayashi
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

9.  Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.

Authors:  P Nanni; G Nicoletti; C De Giovanni; L Landuzzi; E Di Carlo; F Cavallo; S M Pupa; I Rossi; M P Colombo; C Ricci; A Astolfi; P Musiani; G Forni; P L Lollini
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

Review 10.  Assessing CD8 T cell number and dysfunction in the presence of antigen.

Authors:  R M Welsh
Journal:  J Exp Med       Date:  2001-03-05       Impact factor: 14.307

View more
  9 in total

1.  Polymorphisms in toll-like receptor 4 underlie susceptibility to tumor induction by the mouse polyomavirus.

Authors:  Palanivel Velupillai; Chang Kyoo Sung; Erik Andrews; Jennifer Moran; David Beier; Jonathan Kagan; Thomas Benjamin
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

2.  Identification of quantitative trait loci for susceptibility to mouse adenovirus type 1.

Authors:  Amanda R Welton; Elissa J Chesler; Carla Sturkie; Anne U Jackson; Gwen N Hirsch; Katherine R Spindler
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 3.  Pathogen-host standoff: immunity to polyomavirus infection and neoplasia.

Authors:  Aron E Lukacher
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 4.  Immunity to polyomavirus infection: the polyomavirus-mouse model.

Authors:  Phillip A Swanson; Aron E Lukacher; Eva Szomolanyi-Tsuda
Journal:  Semin Cancer Biol       Date:  2009-02-14       Impact factor: 15.707

Review 5.  Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer.

Authors:  Brian S Schaffhausen; Thomas M Roberts
Journal:  Virology       Date:  2008-11-20       Impact factor: 3.616

Review 6.  Review on the relationship between human polyomaviruses-associated tumors and host immune system.

Authors:  Serena Delbue; Manola Comar; Pasquale Ferrante
Journal:  Clin Dev Immunol       Date:  2012-03-25

7.  Ganglioside and Non-ganglioside Mediated Host Responses to the Mouse Polyomavirus.

Authors:  John You; Samantha D O'Hara; Palanivel Velupillai; Sherry Castle; Steven Levery; Robert L Garcea; Thomas Benjamin
Journal:  PLoS Pathog       Date:  2015-10-16       Impact factor: 6.823

Review 8.  Understanding polyomavirus CNS disease - a perspective from mouse models.

Authors:  Katelyn N Ayers; Sarah N Carey; Aron E Lukacher
Journal:  FEBS J       Date:  2021-07-02       Impact factor: 5.622

Review 9.  Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.